ClinicalTrials.gg
CompletedNCT03785756Updated Jun 3, 2024Results posted

Efficacy of 300 mg Ibuprofen Prolonged-Release Tablets for the Treatment of Pain After Surgical Removal of Impacted Third Molars

A Phase 3 interventional study of Ibuprofen 300 mg Oral Tablet and Ibuprofen 200 mg Oral Tablet in Pain, sponsored by Reckitt Benckiser Healthcare (UK) Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-06-03.

Sponsored by Reckitt Benckiser Healthcare (UK) Limited (part of Reckitt) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.

Enrollment
16th of 86
280 · median 100
Started
2019
with 3 others
Phase 3
22 of 86
none open now
Registered
62nd of 86
by date

Among the 86 studies testing ibuprofen in Pain, this one is the 16th largest by enrollment, is one of 4 that started in 2019, is one of 22 in phase 3, and was the 62nd registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About ibuprofen

Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing ibuprofen in Pain, or all of them as a file.
02

Study summary

This is a single centre, randomised, double-blind, double-dummy, parallel group, multiple-dose, active and placebo-controlled efficacy study to evaluate the efficacy and safety of 2×300mg ibuprofen Prolonged Release (PR) tablets in subjects with postoperative dental pain.

Read the detailed description

This is a single centre, randomised, double-blind, double-dummy, parallel group, multiple-dose, active and placebo controlled efficacy study to evaluate the efficacy and safety of ibuprofen 2 × 300 mg ibuprofen PR tablets in subjects with postoperative dental pain.

Eligible subjects will complete all screening procedures within 28 days before the surgery and randomisation.

At Screening, subjects will provide written informed consent to participate in the study before any protocol specified procedures or assessments are completed. On Day 1, subjects who continue to be eligible for study participation after completing screening procedures and assessments will undergo extraction of 2 or more third molars. At least 1 of the third molars must be a fully or partially bone impacted mandibular molar. If only 2 molars are removed, then they must be ipsilateral.

All subjects will receive local anaesthesia (2% lidocaine with 1:100,000 epinephrine). Nitrous oxide will be allowed at the discretion of the investigator. Subjects who experience moderate to severe pain intensity (a score of ≥5 on a numeric rating scale [NRS] from 0-10 where 0 = no pain, 10 = worst pain ever) within 6 hours after surgery and who continue to meet all study entry criteria will be randomised in a 3:3:1 ratio to receive 2 × 300 mg ibuprofen PR tablets every 12 hours (Q12h), 2 × 200 mg ibuprofen immediate release (IR) tablets every 8 hours (Q8h), or placebo. The randomisation will be stratified by baseline pain category (moderate or severe) using a categorical scale that includes the categories of none (0), mild (1-4), moderate (5-7), and severe (8-10).

Subjects will re-assess their baseline pain intensity using the NRS immediately before receiving study drug (pre-dose, Time 0) and their pain intensity (NRS) and pain relief (5-point categorical scale) at the following time points (pre-dose, if at one of the dosing time points of 0, 8, 12 and/or 16 hours): 15, 30, and 45 minutes, and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, and 24 hours after Time 0; and immediately before each dose of rescue medication, if any. For assessments less than 1 hour apart a window of +/-2 min is allowable whilst for assessments at least 1 hour apart a +/-5 min window is allowable.

The double stopwatch method will be used to record the time to perceptible pain relief and time to meaningful pain relief during the 8 hours following the first dose or until subject takes rescue medication. Subjects will complete a global evaluation of study drug 24 hours (+/- 5 minutes) after Time 0 or immediately before the first dose of rescue medication (whichever occurs first). Vital signs will be recorded after the subject has been in a sitting position for 3 minutes at the following times: before surgery, within 30 minutes before Time 0, 12 and 24 hours after Time 0, and/or immediately before the first dose of rescue medication. Adverse events (AEs) will be monitored and recorded from the time of signing of the informed consent form (ICF) until the Follow-up Visit (or Early Termination Visit). During the 24 hours following Time 0, subjects will complete efficacy and safety assessments. Subjects will remain at the study site overnight and will be discharged on Day 2.

Paracetamol / acetaminophen (1000 mg) will be permitted as the initial rescue medication. Subjects will be encouraged to wait at least 60 minutes after receiving study drug before taking rescue medication. If acetaminophen rescue medication is not effective in relieving the subject's pain, 5 mg oxycodone rescue medication may be administered at the discretion of the investigator.

Subjects are not permitted to take any concomitant medications that might confound assessments of pain relief, such as psychotropic drugs, antidepressants, sedative-hypnotics (other than those permitted for conscious sedation), or other analgesics taken within five times of their elimination half-lives (other than those used at the surgery). Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) are permitted if the subject has been on a stable dose for at least four weeks prior to Visit 1 (screening).

Other restrictions include the following: alcohol use is prohibited from 24 hours before surgery until discharge on Day 2; nothing by mouth from midnight before surgery until 1 hour after surgery; clear liquids only are allowed starting 1 hour after surgery until 1 hour after dosing; 1 hour after dosing, the subject's diet may be advanced according to standard practice.

Upon discharge from the study site, subjects may be prescribed pain medication for use at home according to the standard practice of the study site. On Day 8 (± 2 days), subjects will return to the study site for an abbreviated confirmatory physical assessment and AE assessments.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is male or female ≥ 18 and ≤ 50 years of age.
  • Requires extraction of 2 or more third molars. At least 1 of the third molars must be a fully or partially bone impacted mandibular molar. If only 2 molars are removed, then they must be ipsilateral.
  • Experiences moderate to severe pain intensity within 6 hours after surgery, as measured by a numeric rating scale (NRS) score of ≥ 5 on a 0-10 scale.
  • Has a body weight ≥ 45 kg and a (BMI) ≤ 35 kg/m².
  • Female subjects of must have been using an acceptable method of for at least 30 days prior to randomisation and be willing to continue use until at least 48 hours post discharge from the clinic.

To be considered not of child-bearing potential, females must be surgically sterile (defined as bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or (defined as no menses for 12 months without an alternative medical cause).

  • Free of abnormal findings as determined by medical history, physical examination, vital signs, laboratory tests and .
  • Is able to provide written .
  • Is willing and able to comply with study requirements (including diet and smoking restrictions), complete the pain evaluations, remain at the study site overnight, and return for follow up 7 (± 2) days after surgery (Day 8 ± 2 days).

Exclusion criteria

Exclusion Criteria:

  • Known reactions or allergy (e.g., asthma, rhinitis, angioedema or urticaria) in response to nonsteroidal anti-inflammatory drugs (NSAIDs; including ibuprofen), acetylsalicylic acid (aspirin), ingredients of the study drug, or any other drugs used in the study, including anaesthetics and antibiotics that may be required on the day of surgery.
  • A history of active or previous peptic ulceration/ haemorrhage, gastrointestinal bleeding or perforation, heart failure, renal or hepatic failure, uncontrolled hypertension, asthma, nasal polyps, or chronic rhinitis.
  • Has complications from the tooth extraction or any other medical history that, in the opinion of the investigator, would affect the subject's ability to comply or otherwise contraindicate study participation, including but not limited to the following: cardiac, respiratory, gastroenterological, neurological, psychological, immunological, haematological, oncological, or renal disease.
  • Has undergone another dental surgery within 60 days prior to the day of surgery.
  • A positive urine drugs of abuse screen or alcohol breathalyser test at screening and during the study (with the exception of a positive drugs of abuse screen that is a consequence of permitted prescription medicines).
  • If female, has a positive pregnancy test at screening (serum) or on the day of surgery prior to surgery (urine), or is lactating.
  • Has known or suspected (in the opinion of the investigator), history of alcoholism or drug abuse within 2 years of screening or evidence of tolerance or physical dependence before dosing with study drug.
  • Taking any concomitant medications that might confound assessments of pain relief, such as psychotropic drugs, antidepressants, sedative-hypnotics (other than those permitted for conscious sedation), or other analgesics taken within five times of their elimination half-lives. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) are permitted if the subject has been on a stable dose for at least four weeks prior to Visit 1 (screening).
  • Is considered by the investigator, for any reason (including, but not limited to the risks described as precautions, warnings and in the current version of the investigator's brochure (IB) for 300 mg ibuprofen PR tablets), to be an unsuitable candidate to receive the study drug.
  • Has a history of chronic use (defined as daily use for > 2 weeks) of NSAIDs, opiates, or (except inhaled nasal steroids and topical corticosteroids), for any condition within 6 months before dosing with study drug.
  • Has significant difficulties swallowing capsules or tablets or is unable to tolerate oral medication.
  • Subject has received an product or participated in another trial involving a marketed or investigational drug in the 30 days (or for investigational agents with a long half-life, a of 5 half-lives) prior to first drug administration (washout period between studies is defined as the period of time elapsed between the last dose of the previous study and first dose for this study), or if the investigator believes that any previous participation in an investigational study would be to the detriment of the safety of the participant or the conduct of the study.
  • Enrolment of the Investigator, his / her family members, employees, and other dependent persons.
  • Failure to satisfy the investigator of fitness to participate for any other reason.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
280 participants (actual)

Study arms

  • Experimental
    Prolonged Release Group

    2 × 300 mg ibuprofen PR tablets at Hours 0 and 12 2 × placebo of PR tablets at Hours 8 and 16 2 × placebo of IR tablets at Hours 0, 8, 12, and 16

    Drug: Ibuprofen 300 mg Oral Tablet · Drug: Placebo of PR tablet · Drug: Placebo of IR tablet

  • Active comparator
    Immediate Release Group

    2 × 200 mg ibuprofen IR tablets at Hours 0, 8, and 16 2 × placebo of IR tablets at Hour 12 2 × placebo of PR tablets at Hours 0, 8, 12, and 16

    Drug: Ibuprofen 200 mg Oral Tablet · Drug: Placebo of PR tablet · Drug: Placebo of IR tablet

  • Placebo comparator
    Placebo Group

    2 × placebo of PR tablets at Hours 0, 8, 12, and 16 2 × placebo of IR tablets at Hours 0, 8, 12, and 16

    Drug: Placebo of PR tablet · Drug: Placebo of IR tablet

Interventions

  • 2 × 300 mg tablets at Hours 0 and 12

    Also known as: Prolonged Release Tablet

  • 2 × 200 mg tablets at Hours 0, 8, and 16

    Also known as: Nurofen, Immediate Release Tablet

  • DrugPlacebo of PR tablet

    2 tablets up to four times in 24 hours

  • DrugPlacebo of IR tablet

    2 tablets up to four times in 24 hours

06

What researchers measure

Primary outcomes

  1. Summed Pain Intensity Difference Over 0 to 12 Hours (SPID12) After Time 0

    SPID12 was used to compare the test product (2 × 300 mg ibuprofen PR tablets) and comparator product (2 × 200 mg ibuprofen IR tablets three times a day \[TID\]) against the placebo product. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain. SPID12 was calculated using the summed pain intensity difference (change from Time 0) under the NRS-time curve from 15 minutes through 12 hours calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of SPID12 is 0 (no change in pain intensity from Time 0 to 12 hours); the theoretical maximum is 120 (if a patient had a score of 10 \[worst pain intensity\] at baseline, which decreased to 0 \[no pain\] at the next time point and remained at 0 after); a higher SPID12 score indicates a better outcome.

    Time frame: 0-12 hours

Secondary outcomes

  1. Summed Pain Intensity Difference Over 0 to 24 Hours (SPID24) After Time 0

    SPID24 was used to compare the test product (2 × 300 mg ibuprofen PR tablets BID) and comparator product (2 × 200 mg ibuprofen IR tablets TID) against the placebo product. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain. SPID24 was calculated using the summed pain intensity difference (change from Time 0) under the NRS-time curve from 15 minutes through 24 hours calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of SPID24 is 0 (no change in pain intensity from Time 0 to 24 hours); the theoretical maximum is 240 (if a patient had a score of 10 \[worst pain intensity\] at baseline, which decreased to 0 \[no pain\] at the next time point and remained at 0 after).

    Time frame: 0-24 hours

  2. Summed Pain Intensity Difference Over 0 to 4 Hours (SPID4) After Time 0

    SPID4 was used to compare the test product (2 × 300 mg ibuprofen PR tablets BID) and comparator product (2 × 200 mg ibuprofen IR tablets TID) against the placebo product. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain. SPID4 was calculated using the summed pain intensity difference (change from Time 0) under the NRS-time curve from 15 minutes through 4 hours calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of SPID4 is 0 (no change in pain intensity from Time 0 to 4 hours); the theoretical maximum is 40 (if a patient had a score of 10 \[worst pain intensity\] at baseline, which decreased to 0 \[no pain\] at the next time point and remained at 0 after).

    Time frame: 0-4 hours

  3. Summed Pain Intensity Difference Over 0 to 8 Hours (SPID8) After Time 0

    SPID8 was used to compare the test product (2 × 300 mg ibuprofen PR tablets BID) and comparator product (2 × 200 mg ibuprofen IR tablets TID) against the placebo product. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain. SPID8 was calculated using the summed pain intensity difference (change from Time 0) under the NRS-time curve from 15 minutes through 8 hours calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of SPID8 is 0 (no change in pain intensity from Time 0 to 8 hours); the theoretical maximum is 80 (if a patient had a score of 10 \[worst pain intensity\] at baseline, which decreased to 0 \[no pain\] at the next time point and remained at 0 after).

    Time frame: 0-8 hours

  4. Sum of Total Pain Relief Over 0 to 4 Hours (TOTPAR4) After Time 0

    A 5-point categorical Pain Relief Scale (PRS) with choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4 was completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome. TOTPAR4 is the total pain relief measured by the PRS from 15 minutes through 4 hours, calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of TOTPAR4 is 0 (no pain relief from Time 0 to 4 hours); the theoretical maximum is 16 (if a patient experiences maximum pain relief at all time points after baseline).

    Time frame: 0-4 hours

  5. Sum of Total Pain Relief Over 0 to 8 Hours (TOTPAR8) After Time 0

    A 5-point categorical Pain Relief Scale (PRS) with choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4 was completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome. TOTPAR8 is the total pain relief measured by the PRS from 15 minutes through 8 hours, calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of TOTPAR8 is 0 (no pain relief from Time 0 to 8 hours); the theoretical maximum is 32 (if a patient experiences maximum pain relief at all time points after baseline).

    Time frame: 0-8 hours

  6. Sum of Total Pain Relief Over 0 to 12 Hours (TOTPAR12) After Time 0

    A 5-point categorical Pain Relief Scale (PRS) with choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4 was completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome. TOTPAR12 is the total pain relief measured by the PRS from 15 minutes through 12 hours, calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of TOTPAR12 is 0 (no pain relief from Time 0 to 12 hours); the theoretical maximum is 48 (if a patient experiences maximum pain relief at all time points after baseline).

    Time frame: 0-12 hours

  7. Sum of Total Pain Relief Over 0 to 24 Hours (TOTPAR24) After Time 0

    A 5-point categorical Pain Relief Scale (PRS) with choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4 was completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome. TOTPAR24 is the total pain relief measured by the PRS from 15 minutes through 24 hours, calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of TOTPAR24 is 0 (no pain relief from Time 0 to 24 hours); the theoretical maximum is 96 (if a patient experiences maximum pain relief at all time points after baseline).

    Time frame: 0-24 hours

  8. Summed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 4 Hours (SPRID4) After Time 0

    The summed pain relief and intensity difference (sum of TOTPAR and SPID \[SPRID\]) over 0 to 4 hours (SPRID4) was determined by calculating the difference in the PRS at the 4-hour time point and the 0-hour time point (TOTPAR4) and adding this value to the difference in the NRS for pain at the 4-hour time point and the 0-hour time point (SPID4). The minimum value of SPRID4 is 0; the theoretical maximum is 56; a higher SPRID4 score indicates a better outcome.

    Time frame: 0-4 hours

  9. Summed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 8 Hours (SPRID8) After Time 0

    The summed pain relief and intensity difference (sum of TOTPAR and SPID \[SPRID\]) over 0 to 8 hours (SPRID8) was determined by calculating the difference in the PRS at the 8-hour time point and the 0-hour time point (TOTPAR8) and adding this value to the difference in the NRS for pain at the 8-hour time point and the 0-hour time point (SPID8). The minimum value of SPRID8 is 0; the theoretical maximum is 112; a higher SPRID8 score indicates a better outcome.

    Time frame: 0-8 hours

  10. Summed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 12 Hours (SPRID12) After Time 0

    The summed pain relief and intensity difference (sum of TOTPAR and SPID \[SPRID\]) over 0 to 12 hours (SPRID12) was determined by calculating the difference in the PRS at the 12-hour time point and the 0-hour time point (TOTPAR12) and adding this value to the difference in the NRS for pain at the 12-hour time point and the 0-hour time point (SPID12). The minimum value of SPRID12 is 0; the theoretical maximum 168; a higher SPRID12 score indicates a better outcome.

    Time frame: 0-12 hours

  11. Summed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 24 Hours (SPRID24) After Time 0

    The summed pain relief and intensity difference (sum of TOTPAR and SPID \[SPRID\]) over 0 to 24 hours (SPRID24) was determined by calculating the difference in the PRS at the 24-hour time point and the 0-hour time point (TOTPAR24) and adding this value to the difference in the NRS for pain at the 24-hour time point and the 0-hour time point (SPID24). The minimum value of SPRID24 is 0; the theoretical maximum is 336; a higher SPRID24 score indicates a better outcome.

    Time frame: 0-24 hours

  12. Number of Subjects With Response to Study Drug

    A responder was defined as a subject with ≥30% improvement in pain intensity at the 8-hour assessment without rescue medication during the first 8 hours. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain.

    Time frame: 0-8 hours

  13. Numeric Rating Scale (NRS) Pain Intensity Difference (PID) at Each Time Point After Time 0

    An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain, and the PID (the difference in NRS pain intensity between each time point and Time 0) at each time point was calculated.

    Time frame: 0-24 hours

  14. Pain Intensity Score at Each Scheduled Time Point After Time 0

    Pain intensity score at each scheduled time point will be assessed using a numeric rating scale (NRS) for pain. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain.

    Time frame: 0-24 hours

  15. Pain Relief at Each Scheduled Time Point After Time 0

    Pain relief score at each scheduled time point after Time 0 was measured using the Pain Relief Scale (PRS). The PRS was used to measure pain relief and is a 5-point categorical scale, with response choices of: none = 0; a little = 1; some = 2; a lot = 3; and complete = 4 to be completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome.

    Time frame: 0-24 hours

  16. Peak Pain Relief

    Peak pain relief at each time point was measured using the Pain Relief Scale (PRS). The PRS was used to measure pain relief and is a 5-point categorical scale, response choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4 to be completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome. For each subject, peak pain relief was calculated as the maximum pain relief over all PRS assessments, and summarised by counts (and percentages) for each PRS score. Peak pain relief was calculated from PRS scores that were adjusted for rescue medication usage using windowed worst observation carried forward (WOCF).

    Time frame: 0-24 hours

  17. Time to Onset of Analgesia (Measured as Time to Perceptible Pain Relief Confirmed by Time to Meaningful Pain Relief) Using Double Stopwatch

    Two stopwatches were started immediately after the subject swallowed the study drug. Subjects were instructed to, "Stop the first stopwatch when you first feel any pain relief whatsoever. This does not mean you feel completely better, although you might, but when you first feel any relief in the pain you have now" (perceptible pain relief), and then, "Stop the second stopwatch when you feel the pain relief is meaningful to you" (meaningful pain relief). If the stopwatches were not stopped within 8 hours after Time 0 use of the stopwatches was discontinued. If the subject had meaningful pain relief (i.e., pressed both stopwatches) then time to onset of analgesia was date/time of perceptible pain relief - date/time of the first dose of study drug. Values presented are from Kaplan-Meier estimates.

    Time frame: 0-24 hours

  18. Time to First Perceptible Pain Relief

    Two stopwatches were started immediately after the subject swallowed the study drug. Subjects were instructed to, "Stop the first stopwatch when you first feel any pain relief whatsoever. This does not mean you feel completely better, although you might, but when you first feel any relief in the pain you have now" (perceptible pain relief). Time to first perceptible pain relief was date/time of the first reported pain relief (any) as assessed by the subject (i.e., when the subject stopped the first stopwatch, irrespective of the second) - date/time of the first dose of study drug. If the stopwatch were not stopped within 8 hours after Time 0, use of the stopwatches was discontinued. Values presented are from Kaplan-Meier estimates.

    Time frame: 0-8 hours

  19. Time to Meaningful Pain Relief

    Two stopwatches were started immediately after the subject swallowed the study drug. Each subject was instructed, "Stop the second stopwatch when you feel the pain relief is meaningful to you" (meaningful pain relief). Time to meaningful pain relief was the date/time of the first reported meaningful (subjective) pain relief as assessed by the subject (i.e., when the subject stopped the second stopwatch) - date/time of the first dose of study drug. If the stopwatches were not stopped within 8 hours after Time 0 use of the stopwatches was discontinued. Values presented are from Kaplan-Meier estimates.

    Time frame: 0-8 hours

  20. Time to Peak Pain Relief

    The PRS was used to measure pain relief and is a 5-point categorical scale, with response choices of: none = 0; a little = 1; some = 2; a lot = 3; and complete = 4 to be completed in response to the question "How much relief have you had since your starting pain?". A higher score indicates greater pain. Time to peak pain relief was the time when peak pain relief (PPR) first occurred. Values presented are from Kaplan-Meier estimates.

    Time frame: 0-24 hours

  21. Number of Subjects Using Rescue Medication

    After randomisation and administration of study drug, paracetamol/acetaminophen (1000 mg) was permitted as the initial rescue medication. Subjects were encouraged to wait at least 60 minutes after receiving study drug before taking rescue medication. If acetaminophen rescue medication was not effective in relieving the subject's pain, 5 mg oxycodone rescue medication was administered at the discretion of the investigator. At the investigator's discretion, repeat doses of rescue medication were also administered as required.

    Time frame: 0-24 hours

  22. Time to First Use of Rescue Medication (Median and 95% Confidence Interval)

    Time to first use of rescue medication, in hours.

    Time frame: 0-24 hours

  23. Time to First Use of Rescue Medication (Hazard Ratios Versus Placebo)

    Time to first use of rescue medication, in hours. Values presented are the hazard ratios, calculated from Cox proportional hazards model with treatment group as a categorical factor and baseline pain as a continuous covariate. A hazard ratio of \<1 means that when subjects did take rescue medication, subjects in the ibuprofen groups refrained from taking rescue medication for longer than subjects in the placebo group. A hazard ratio of \>1 means that when subjects did take rescue medication, subjects in the placebo group refrained from taking rescue medication for longer than subjects in the ibuprofen groups.

    Time frame: 0-24 hours

Other outcomes

  1. Incidence of Treatment Emergent Adverse Events as Assessed by Patient Response to Questions and Spontaneous Reporting of TEAEs

    Incidence of treatment emergent adverse events (TEAEs). Data listings will be provided for protocol specified safety data.

    Time frame: 0-10 days

  2. Vital Signs Measurements - Blood Pressure in mm/Hg

    Incidence of changes in vital sign measurements. Descriptive statistics will be provided at each scheduled time point for each treatment group. Changes from Baseline for vital signs will be calculated for each subject.

    Time frame: 0-10 days

  3. Vital Signs Measurements - Heart Rate in Beats Per Minute

    Incidence of changes in vital sign measurements. Descriptive statistics will be provided at each scheduled time point for each treatment group. Changes from Baseline for vital signs will be calculated for each subject.

    Time frame: 0-10 days

  4. Vital Signs Measurements - Respiratory Rate in Breaths Per Minute

    Incidence of changes in vital sign measurements. Descriptive statistics will be provided at each scheduled time point for each treatment group. Changes from Baseline for vital signs will be calculated for each subject.

    Time frame: 0-10 days

  5. Vital Signs Measurements - Body Temperature in ºC

    Incidence of changes in vital sign measurements. Descriptive statistics will be provided at each scheduled time point for each treatment group. Changes from Baseline for vital signs will be calculated for each subject.

    Time frame: 0-10 days

  6. Global Evaluation of Efficacy Using 5 Point Categorical Scale

    Patient's global evaluation of study drug using 5 point categorical scale, response choices of 0 = poor, 1 = fair, 2 = good, 3 = very good, or 4 = excellent to be completed by the patient in response to the question "How effective do you think the study drug is as a treatment for pain?". Subjects will complete the global evaluation of study drug 24 hours after Time 0 or immediately before the first dose of rescue medication (whichever occurs first).

    Time frame: 0-24 hours

07

Results

Posted Jun 3, 2024

Participant flow

Participant flow — Overall Study
MilestoneProlonged Release GroupImmediate Release GroupPlacebo Group
Started12012040
Completed11111235
Not completed985

Outcome measures

PrimarySummed Pain Intensity Difference Over 0 to 12 Hours (SPID12) After Time 0

SPID12 was used to compare the test product (2 × 300 mg ibuprofen PR tablets) and comparator product (2 × 200 mg ibuprofen IR tablets three times a day \[TID\]) against the placebo product. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain. SPID12 was calculated using the summed pain intensity difference (change from Time 0) under the NRS-time curve from 15 minutes through 12 hours calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of SPID12 is 0 (no change in pain intensity from Time 0 to 12 hours); the theoretical maximum is 120 (if a patient had a score of 10 \[worst pain intensity\] at baseline, which decreased to 0 \[no pain\] at the next time point and remained at 0 after); a higher SPID12 score indicates a better outcome.

Time frame:
0-12 hours
Reported as:
Mean · score on a scale*hours
Summed Pain Intensity Difference Over 0 to 12 Hours (SPID12) After Time 0
score on a scale*hoursProlonged Release GroupImmediate Release GroupPlacebo Group
Summed Pain Intensity Difference Over 0 to 12 Hours (SPID12) After Time 051.84 ± 21.45756.33 ± 18.76919.11 ± 24.630
Statistical analysis
  • Prolonged Release Group vs Placebo Group · ANCOVA · p = <0.0001 · Mean difference (final values): 34.05 · 95% CI 26.72 to 41.38Estimates from an ANCOVA model with SPID12 score as the dependent variable. Terms for treatment and baseline pain score were included as covariates.
SecondarySummed Pain Intensity Difference Over 0 to 24 Hours (SPID24) After Time 0

SPID24 was used to compare the test product (2 × 300 mg ibuprofen PR tablets BID) and comparator product (2 × 200 mg ibuprofen IR tablets TID) against the placebo product. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain. SPID24 was calculated using the summed pain intensity difference (change from Time 0) under the NRS-time curve from 15 minutes through 24 hours calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of SPID24 is 0 (no change in pain intensity from Time 0 to 24 hours); the theoretical maximum is 240 (if a patient had a score of 10 \[worst pain intensity\] at baseline, which decreased to 0 \[no pain\] at the next time point and remained at 0 after).

Time frame:
0-24 hours
Reported as:
Mean · score on a scale*hours
Summed Pain Intensity Difference Over 0 to 24 Hours (SPID24) After Time 0
score on a scale*hoursProlonged Release GroupImmediate Release GroupPlacebo Group
Summed Pain Intensity Difference Over 0 to 24 Hours (SPID24) After Time 0115.75 ± 46.146121.90 ± 37.26364.32 ± 55.070
SecondarySummed Pain Intensity Difference Over 0 to 4 Hours (SPID4) After Time 0

SPID4 was used to compare the test product (2 × 300 mg ibuprofen PR tablets BID) and comparator product (2 × 200 mg ibuprofen IR tablets TID) against the placebo product. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain. SPID4 was calculated using the summed pain intensity difference (change from Time 0) under the NRS-time curve from 15 minutes through 4 hours calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of SPID4 is 0 (no change in pain intensity from Time 0 to 4 hours); the theoretical maximum is 40 (if a patient had a score of 10 \[worst pain intensity\] at baseline, which decreased to 0 \[no pain\] at the next time point and remained at 0 after).

Time frame:
0-4 hours
Reported as:
Mean · score on a scale*hours
Summed Pain Intensity Difference Over 0 to 4 Hours (SPID4) After Time 0
score on a scale*hoursProlonged Release GroupImmediate Release GroupPlacebo Group
Summed Pain Intensity Difference Over 0 to 4 Hours (SPID4) After Time 014.68 ± 9.75216.99 ± 7.8841.24 ± 8.346
SecondarySummed Pain Intensity Difference Over 0 to 8 Hours (SPID8) After Time 0

SPID8 was used to compare the test product (2 × 300 mg ibuprofen PR tablets BID) and comparator product (2 × 200 mg ibuprofen IR tablets TID) against the placebo product. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain. SPID8 was calculated using the summed pain intensity difference (change from Time 0) under the NRS-time curve from 15 minutes through 8 hours calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of SPID8 is 0 (no change in pain intensity from Time 0 to 8 hours); the theoretical maximum is 80 (if a patient had a score of 10 \[worst pain intensity\] at baseline, which decreased to 0 \[no pain\] at the next time point and remained at 0 after).

Time frame:
0-8 hours
Reported as:
Mean · score on a scale*hours
Summed Pain Intensity Difference Over 0 to 8 Hours (SPID8) After Time 0
score on a scale*hoursProlonged Release GroupImmediate Release GroupPlacebo Group
Summed Pain Intensity Difference Over 0 to 8 Hours (SPID8) After Time 033.13 ± 16.19534.48 ± 13.00111.00 ± 14.571
SecondarySum of Total Pain Relief Over 0 to 4 Hours (TOTPAR4) After Time 0

A 5-point categorical Pain Relief Scale (PRS) with choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4 was completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome. TOTPAR4 is the total pain relief measured by the PRS from 15 minutes through 4 hours, calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of TOTPAR4 is 0 (no pain relief from Time 0 to 4 hours); the theoretical maximum is 16 (if a patient experiences maximum pain relief at all time points after baseline).

Time frame:
0-4 hours
Reported as:
Mean · score on a scale*hours
Sum of Total Pain Relief Over 0 to 4 Hours (TOTPAR4) After Time 0
score on a scale*hoursProlonged Release GroupImmediate Release GroupPlacebo Group
Sum of Total Pain Relief Over 0 to 4 Hours (TOTPAR4) After Time 08.08 ± 4.3378.98 ± 3.3651.98 ± 3.285
SecondarySum of Total Pain Relief Over 0 to 8 Hours (TOTPAR8) After Time 0

A 5-point categorical Pain Relief Scale (PRS) with choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4 was completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome. TOTPAR8 is the total pain relief measured by the PRS from 15 minutes through 8 hours, calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of TOTPAR8 is 0 (no pain relief from Time 0 to 8 hours); the theoretical maximum is 32 (if a patient experiences maximum pain relief at all time points after baseline).

Time frame:
0-8 hours
Reported as:
Mean · score on a scale*hours
Sum of Total Pain Relief Over 0 to 8 Hours (TOTPAR8) After Time 0
score on a scale*hoursProlonged Release GroupImmediate Release GroupPlacebo Group
Sum of Total Pain Relief Over 0 to 8 Hours (TOTPAR8) After Time 018.08 ± 7.31418.41 ± 5.7647.89 ± 5.642
SecondarySum of Total Pain Relief Over 0 to 12 Hours (TOTPAR12) After Time 0

A 5-point categorical Pain Relief Scale (PRS) with choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4 was completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome. TOTPAR12 is the total pain relief measured by the PRS from 15 minutes through 12 hours, calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of TOTPAR12 is 0 (no pain relief from Time 0 to 12 hours); the theoretical maximum is 48 (if a patient experiences maximum pain relief at all time points after baseline).

Time frame:
0-12 hours
Reported as:
Mean · score on a scale*hours
Sum of Total Pain Relief Over 0 to 12 Hours (TOTPAR12) After Time 0
score on a scale*hoursProlonged Release GroupImmediate Release GroupPlacebo Group
Sum of Total Pain Relief Over 0 to 12 Hours (TOTPAR12) After Time 028.13 ± 9.98129.981 ± 8.53812.76 ± 9.270
SecondarySum of Total Pain Relief Over 0 to 24 Hours (TOTPAR24) After Time 0

A 5-point categorical Pain Relief Scale (PRS) with choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4 was completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome. TOTPAR24 is the total pain relief measured by the PRS from 15 minutes through 24 hours, calculated using the linear trapezoidal rule and the actual time points, where Time 0 is the time of the first dose of study drug. The minimum value of TOTPAR24 is 0 (no pain relief from Time 0 to 24 hours); the theoretical maximum is 96 (if a patient experiences maximum pain relief at all time points after baseline).

Time frame:
0-24 hours
Reported as:
Mean · score on a scale*hours
Sum of Total Pain Relief Over 0 to 24 Hours (TOTPAR24) After Time 0
score on a scale*hoursProlonged Release GroupImmediate Release GroupPlacebo Group
Sum of Total Pain Relief Over 0 to 24 Hours (TOTPAR24) After Time 062.32 ± 20.50464.63 ± 16.77436.96 ± 22.153
SecondarySummed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 4 Hours (SPRID4) After Time 0

The summed pain relief and intensity difference (sum of TOTPAR and SPID \[SPRID\]) over 0 to 4 hours (SPRID4) was determined by calculating the difference in the PRS at the 4-hour time point and the 0-hour time point (TOTPAR4) and adding this value to the difference in the NRS for pain at the 4-hour time point and the 0-hour time point (SPID4). The minimum value of SPRID4 is 0; the theoretical maximum is 56; a higher SPRID4 score indicates a better outcome.

Time frame:
0-4 hours
Reported as:
Mean · score on a scale*hours
Summed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 4 Hours (SPRID4) After Time 0
score on a scale*hoursProlonged Release GroupImmediate Release GroupPlacebo Group
Summed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 4 Hours (SPRID4) After Time 022.76 ± 13.87025.97 ± 11.0113.22 ± 11.464
SecondarySummed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 8 Hours (SPRID8) After Time 0

The summed pain relief and intensity difference (sum of TOTPAR and SPID \[SPRID\]) over 0 to 8 hours (SPRID8) was determined by calculating the difference in the PRS at the 8-hour time point and the 0-hour time point (TOTPAR8) and adding this value to the difference in the NRS for pain at the 8-hour time point and the 0-hour time point (SPID8). The minimum value of SPRID8 is 0; the theoretical maximum is 112; a higher SPRID8 score indicates a better outcome.

Time frame:
0-8 hours
Reported as:
Mean · score on a scale*hours
Summed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 8 Hours (SPRID8) After Time 0
score on a scale*hoursProlonged Release GroupImmediate Release GroupPlacebo Group
Summed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 8 Hours (SPRID8) After Time 051.21 ± 22.98552.88 ± 18.15618.89 ± 19.916
SecondarySummed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 12 Hours (SPRID12) After Time 0

The summed pain relief and intensity difference (sum of TOTPAR and SPID \[SPRID\]) over 0 to 12 hours (SPRID12) was determined by calculating the difference in the PRS at the 12-hour time point and the 0-hour time point (TOTPAR12) and adding this value to the difference in the NRS for pain at the 12-hour time point and the 0-hour time point (SPID12). The minimum value of SPRID12 is 0; the theoretical maximum 168; a higher SPRID12 score indicates a better outcome.

Time frame:
0-12 hours
Reported as:
Mean · score on a scale*hours
Summed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 12 Hours (SPRID12) After Time 0
score on a scale*hoursProlonged Release GroupImmediate Release GroupPlacebo Group
Summed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 12 Hours (SPRID12) After Time 079.97 ± 30.64386.24 ± 26.26031.87 ± 33.539
SecondarySummed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 24 Hours (SPRID24) After Time 0

The summed pain relief and intensity difference (sum of TOTPAR and SPID \[SPRID\]) over 0 to 24 hours (SPRID24) was determined by calculating the difference in the PRS at the 24-hour time point and the 0-hour time point (TOTPAR24) and adding this value to the difference in the NRS for pain at the 24-hour time point and the 0-hour time point (SPID24). The minimum value of SPRID24 is 0; the theoretical maximum is 336; a higher SPRID24 score indicates a better outcome.

Time frame:
0-24 hours
Reported as:
Mean · score on a scale*hours
Summed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 24 Hours (SPRID24) After Time 0
score on a scale*hoursProlonged Release GroupImmediate Release GroupPlacebo Group
Summed Pain Relief and Intensity Difference (Sum of TOTPAR and SPID [SPRID]) Over 0 to 24 Hours (SPRID24) After Time 0178.07 ± 64.783186.53 ± 51.842101.28 ± 76.562
SecondaryNumber of Subjects With Response to Study Drug

A responder was defined as a subject with ≥30% improvement in pain intensity at the 8-hour assessment without rescue medication during the first 8 hours. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain.

Time frame:
0-8 hours
Reported as:
Count of participants · Participants
Number of Subjects With Response to Study Drug
ParticipantsProlonged Release GroupImmediate Release GroupPlacebo Group
Number of Subjects With Response to Study Drug81765
SecondaryNumeric Rating Scale (NRS) Pain Intensity Difference (PID) at Each Time Point After Time 0

An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain, and the PID (the difference in NRS pain intensity between each time point and Time 0) at each time point was calculated.

Time frame:
0-24 hours
Reported as:
Mean · score on a scale
Numeric Rating Scale (NRS) Pain Intensity Difference (PID) at Each Time Point After Time 0
score on a scaleProlonged Release GroupImmediate Release GroupPlacebo Group
PID 15 Minutes Post-dose0.4 ± 0.970.5 ± 1.140.2 ± 0.99
PID 30 Minutes Post-dose1.4 ± 1.791.5 ± 1.900.3 ± 1.34
PID 45 Minutes Post-dose2.1 ± 2.372.6 ± 2.250.3 ± 1.57
PID 1 Hour Post-dose2.9 ± 2.593.5 ± 2.510.4 ± 2.02
PID 1.5 Hours Post-dose3.8 ± 2.764.4 ± 2.410.3 ± 2.09
PID 2 Hours Post-dose4.3 ± 2.785.0 ± 2.380.4 ± 2.39
PID 3 Hours Post-dose4.5 ± 2.815.2 ± 2.270.3 ± 2.56
PID 4 Hours Post-dose4.8 ± 2.925.2 ± 2.270.3 ± 2.59
PID 5 Hours Post-dose4.6 ± 2.795.0 ± 2.160.6 ± 2.84
PID 6 Hours Post-dose5.1 ± 2.104.8 ± 2.193.2 ± 3.12
PID 7 Hours Post-dose5.0 ± 2.254.3 ± 2.293.0 ± 2.70
PID 8 Hours Post-dose4.6 ± 2.323.6 ± 2.313.0 ± 2.73
PID 10 Hours Post-dose5.1 ± 2.105.4 ± 2.032.0 ± 2.75
PID 12 Hours Post-dose4.6 ± 2.215.6 ± 1.922.1 ± 3.60
PID 16 Hours Post-dose5.2 ± 2.344.8 ± 2.263.2 ± 2.99
PID 24 Hours Post-dose5.6 ± 2.205.9 ± 1.683.9 ± 3.24
SecondaryPain Intensity Score at Each Scheduled Time Point After Time 0

Pain intensity score at each scheduled time point will be assessed using a numeric rating scale (NRS) for pain. An 11-point (0-10) numeric rating scale (NRS) for pain was used to assess pain intensity, where a higher score indicates a greater amount of pain.

Time frame:
0-24 hours
Reported as:
Mean · score on a scale
Pain Intensity Score at Each Scheduled Time Point After Time 0
score on a scaleProlonged Release GroupImmediate Release GroupPlacebo Group
Pain Intensity Score at Baseline7.5 ± 1.237.6 ± 1.177.8 ± 1.12
Pain Intensity Score 15 Minutes Post-dose7.1 ± 1.597.1 ± 1.617.6 ± 1.33
Pain Intensity Score 30 Minutes Post-dose6.1 ± 2.066.1 ± 2.247.5 ± 1.62
Pain Intensity Score 45 Minutes Post-dose5.5 ± 2.505.0 ± 2.577.6 ± 1.74
Pain Intensity Score 1 Hour Post-dose4.7 ± 2.684.0 ± 2.677.4 ± 2.06
Pain Intensity Score 1.5 Hours Post-dose3.8 ± 2.793.2 ± 2.487.5 ± 2.08
Pain Intensity Score 2 Hours Post-dose3.2 ± 2.792.6 ± 2.397.4 ± 2.37
Pain Intensity Score 3 Hours Post-dose2.9 ± 2.842.4 ± 2.267.6 ± 2.46
Pain Intensity Score 4 Hours Post-dose2.7 ± 2.892.3 ± 2.307.6 ± 2.52
Pain Intensity Score 5 Hours Post-dose2.9 ± 2.882.6 ± 2.287.2 ± 2.71
Pain Intensity Score 6 Hours Post-dose2.4 ± 2.052.8 ± 2.164.7 ± 2.78
Pain Intensity Score 7 Hours Post-dose2.5 ± 2.323.3 ± 2.344.8 ± 2.53
Pain Intensity Score 8 Hours Post-dose2.9 ± 2.464.0 ± 2.484.8 ± 2.54
Pain Intensity Score 10 Hours Post-dose2.4 ± 2.342.2 ± 1.925.8 ± 2.53
Pain Intensity Score 12 Hours Post-dose2.9 ± 2.302.0 ± 1.805.7 ± 3.18
Pain Intensity Score 16 Hours Post-dose2.3 ± 2.262.8 ± 2.234.6 ± 2.74
Pain Intensity Score 24 Hours Post-dose1.8 ± 2.091.7 ± 1.533.9 ± 3.01
SecondaryPain Relief at Each Scheduled Time Point After Time 0

Pain relief score at each scheduled time point after Time 0 was measured using the Pain Relief Scale (PRS). The PRS was used to measure pain relief and is a 5-point categorical scale, with response choices of: none = 0; a little = 1; some = 2; a lot = 3; and complete = 4 to be completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome.

Time frame:
0-24 hours
Reported as:
Mean · score on a scale
Pain Relief at Each Scheduled Time Point After Time 0
score on a scaleProlonged Release GroupImmediate Release GroupPlacebo Group
15 Minutes Post-dose0.3 ± 0.600.4 ± 0.670.3 ± 0.44
30 Minutes Post-dose0.9 ± 0.921.0 ± 0.930.4 ± 0.72
45 Minutes Post-dose1.3 ± 1.101.6 ± 1.150.5 ± 0.79
1 Hour Post-dose1.7 ± 1.221.9 ± 1.210.6 ± 0.88
1.5 Hours Post-dose2.1 ± 1.262.4 ± 1.130.5 ± 0.88
2 Hours Post-dose2.3 ± 1.222.6 ± 1.080.6 ± 1.00
3 Hours Post-dose2.5 ± 1.312.7 ± 0.970.5 ± 1.00
4 Hours Post-dose2.6 ± 1.392.7 ± 1.000.5 ± 0.97
5 Hours Post-dose2.5 ± 1.342.6 ± 1.010.7 ± 1.10
6 Hours Post-dose2.7 ± 0.962.5 ± 0.991.8 ± 1.29
7 Hours Post-dose2.7 ± 1.062.3 ± 1.121.7 ± 1.21
8 Hours Post-dose2.5 ± 1.112.1 ± 1.151.7 ± 1.23
10 Hours Post-dose2.7 ± 1.062.9 ± 0.941.3 ± 1.16
12 Hours Post-dose2.5 ± 1.042.9 ± 0.881.2 ± 1.27
16 Hours Post-dose2.8 ± 1.062.6 ± 1.031.8 ± 1.34
24 Hours Post-dose3.0 ± 0.963.1 ± 0.742.1 ± 1.43
SecondaryPeak Pain Relief

Peak pain relief at each time point was measured using the Pain Relief Scale (PRS). The PRS was used to measure pain relief and is a 5-point categorical scale, response choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4 to be completed in response to the question "How much relief have you had since your starting pain?". Higher scores indicate a better outcome. For each subject, peak pain relief was calculated as the maximum pain relief over all PRS assessments, and summarised by counts (and percentages) for each PRS score. Peak pain relief was calculated from PRS scores that were adjusted for rescue medication usage using windowed worst observation carried forward (WOCF).

Time frame:
0-24 hours
Reported as:
Count of participants · Participants
Peak Pain Relief
ParticipantsProlonged Release GroupImmediate Release GroupPlacebo Group
None210
A little relief212
Some relief838
A lot of relief496223
Complete relief59536
SecondaryTime to Onset of Analgesia (Measured as Time to Perceptible Pain Relief Confirmed by Time to Meaningful Pain Relief) Using Double Stopwatch

Two stopwatches were started immediately after the subject swallowed the study drug. Subjects were instructed to, "Stop the first stopwatch when you first feel any pain relief whatsoever. This does not mean you feel completely better, although you might, but when you first feel any relief in the pain you have now" (perceptible pain relief), and then, "Stop the second stopwatch when you feel the pain relief is meaningful to you" (meaningful pain relief). If the stopwatches were not stopped within 8 hours after Time 0 use of the stopwatches was discontinued. If the subject had meaningful pain relief (i.e., pressed both stopwatches) then time to onset of analgesia was date/time of perceptible pain relief - date/time of the first dose of study drug. Values presented are from Kaplan-Meier estimates.

Time frame:
0-24 hours
Reported as:
Median · Hours
Time to Onset of Analgesia (Measured as Time to Perceptible Pain Relief Confirmed by Time to Meaningful Pain Relief) Using Double Stopwatch
HoursProlonged Release GroupImmediate Release GroupPlacebo Group
Time to Onset of Analgesia (Measured as Time to Perceptible Pain Relief Confirmed by Time to Meaningful Pain Relief) Using Double Stopwatch0.48 (0.42 to 0.53)0.47 (0.37 to 0.51)NA (NA to NA)
SecondaryTime to First Perceptible Pain Relief

Two stopwatches were started immediately after the subject swallowed the study drug. Subjects were instructed to, "Stop the first stopwatch when you first feel any pain relief whatsoever. This does not mean you feel completely better, although you might, but when you first feel any relief in the pain you have now" (perceptible pain relief). Time to first perceptible pain relief was date/time of the first reported pain relief (any) as assessed by the subject (i.e., when the subject stopped the first stopwatch, irrespective of the second) - date/time of the first dose of study drug. If the stopwatch were not stopped within 8 hours after Time 0, use of the stopwatches was discontinued. Values presented are from Kaplan-Meier estimates.

Time frame:
0-8 hours
Reported as:
Median · Hours
Time to First Perceptible Pain Relief
HoursProlonged Release GroupImmediate Release GroupPlacebo Group
Time to First Perceptible Pain Relief0.47 (0.09 to 5.11)0.46 (0.04 to 3.96)1.01 (0.08 to 3.28)
SecondaryTime to Meaningful Pain Relief

Two stopwatches were started immediately after the subject swallowed the study drug. Each subject was instructed, "Stop the second stopwatch when you feel the pain relief is meaningful to you" (meaningful pain relief). Time to meaningful pain relief was the date/time of the first reported meaningful (subjective) pain relief as assessed by the subject (i.e., when the subject stopped the second stopwatch) - date/time of the first dose of study drug. If the stopwatches were not stopped within 8 hours after Time 0 use of the stopwatches was discontinued. Values presented are from Kaplan-Meier estimates.

Time frame:
0-8 hours
Reported as:
Median · Hours
Time to Meaningful Pain Relief
HoursProlonged Release GroupImmediate Release GroupPlacebo Group
Time to Meaningful Pain Relief1.25 (0.21 to 8.00)0.99 (0.29 to 8.00)2.88 (0.32 to 7.95)
SecondaryTime to Peak Pain Relief

The PRS was used to measure pain relief and is a 5-point categorical scale, with response choices of: none = 0; a little = 1; some = 2; a lot = 3; and complete = 4 to be completed in response to the question "How much relief have you had since your starting pain?". A higher score indicates greater pain. Time to peak pain relief was the time when peak pain relief (PPR) first occurred. Values presented are from Kaplan-Meier estimates.

Time frame:
0-24 hours
Reported as:
Median · Hours
Time to Peak Pain Relief
HoursProlonged Release GroupImmediate Release GroupPlacebo Group
Time to Peak Pain Relief3.00 (2.03 to 3.97)2.02 (1.98 to 3.00)5.02 (3.02 to 11.97)
SecondaryNumber of Subjects Using Rescue Medication

After randomisation and administration of study drug, paracetamol/acetaminophen (1000 mg) was permitted as the initial rescue medication. Subjects were encouraged to wait at least 60 minutes after receiving study drug before taking rescue medication. If acetaminophen rescue medication was not effective in relieving the subject's pain, 5 mg oxycodone rescue medication was administered at the discretion of the investigator. At the investigator's discretion, repeat doses of rescue medication were also administered as required.

Time frame:
0-24 hours
Reported as:
Count of participants · Participants
Number of Subjects Using Rescue Medication
ParticipantsProlonged Release GroupImmediate Release GroupPlacebo Group
Number of Subjects Using Rescue Medication301932
SecondaryTime to First Use of Rescue Medication (Median and 95% Confidence Interval)

Time to first use of rescue medication, in hours.

Time frame:
0-24 hours
Reported as:
Median · hours
Time to First Use of Rescue Medication (Median and 95% Confidence Interval)
hoursProlonged Release GroupImmediate Release GroupPlacebo Group
Time to First Use of Rescue Medication (Median and 95% Confidence Interval)NA (NA to NA)NA (NA to NA)1.37 (1.20 to 2.38)
SecondaryTime to First Use of Rescue Medication (Hazard Ratios Versus Placebo)

Time to first use of rescue medication, in hours. Values presented are the hazard ratios, calculated from Cox proportional hazards model with treatment group as a categorical factor and baseline pain as a continuous covariate. A hazard ratio of \<1 means that when subjects did take rescue medication, subjects in the ibuprofen groups refrained from taking rescue medication for longer than subjects in the placebo group. A hazard ratio of \>1 means that when subjects did take rescue medication, subjects in the placebo group refrained from taking rescue medication for longer than subjects in the ibuprofen groups.

Time frame:
0-24 hours
Reported as:
Number · Hazard ratio versus placebo
Time to First Use of Rescue Medication (Hazard Ratios Versus Placebo)
Hazard ratio versus placeboProlonged Release GroupImmediate Release GroupPlacebo Group
Time to First Use of Rescue Medication (Hazard Ratios Versus Placebo)0.17 (0.10 to 0.29)0.10 (0.06 to 0.18)NA (NA to NA)
Other pre-specifiedIncidence of Treatment Emergent Adverse Events as Assessed by Patient Response to Questions and Spontaneous Reporting of TEAEs

Incidence of treatment emergent adverse events (TEAEs). Data listings will be provided for protocol specified safety data.

Time frame:
0-10 days

Results for this outcome have not been posted.

Other pre-specifiedVital Signs Measurements - Blood Pressure in mm/Hg

Incidence of changes in vital sign measurements. Descriptive statistics will be provided at each scheduled time point for each treatment group. Changes from Baseline for vital signs will be calculated for each subject.

Time frame:
0-10 days

Results for this outcome have not been posted.

Other pre-specifiedVital Signs Measurements - Heart Rate in Beats Per Minute

Incidence of changes in vital sign measurements. Descriptive statistics will be provided at each scheduled time point for each treatment group. Changes from Baseline for vital signs will be calculated for each subject.

Time frame:
0-10 days

Results for this outcome have not been posted.

Other pre-specifiedVital Signs Measurements - Respiratory Rate in Breaths Per Minute

Incidence of changes in vital sign measurements. Descriptive statistics will be provided at each scheduled time point for each treatment group. Changes from Baseline for vital signs will be calculated for each subject.

Time frame:
0-10 days

Results for this outcome have not been posted.

Other pre-specifiedVital Signs Measurements - Body Temperature in ºC

Incidence of changes in vital sign measurements. Descriptive statistics will be provided at each scheduled time point for each treatment group. Changes from Baseline for vital signs will be calculated for each subject.

Time frame:
0-10 days

Results for this outcome have not been posted.

Other pre-specifiedGlobal Evaluation of Efficacy Using 5 Point Categorical Scale

Patient's global evaluation of study drug using 5 point categorical scale, response choices of 0 = poor, 1 = fair, 2 = good, 3 = very good, or 4 = excellent to be completed by the patient in response to the question "How effective do you think the study drug is as a treatment for pain?". Subjects will complete the global evaluation of study drug 24 hours after Time 0 or immediately before the first dose of rescue medication (whichever occurs first).

Time frame:
0-24 hours

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events were monitored and recorded from the time of signing of the informed consent form until the Follow-up Visit (or Early Termination Visit); a period of up to 30 days. Only treatment-emergent adverse events (those that started or worsened in intensity or relationship to treatment on or after the first dose of study drug) are reported here.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prolonged Release Group0/120 (0%)0/120 (0%)11/120 (9.2%)
Immediate Release Group0/120 (0%)0/120 (0%)15/120 (12.5%)
Placebo Group0/39 (0%)0/39 (0%)12/39 (30.8%)
Most frequent other events
Showing 10 of 27
Most frequent other events
EventProlonged Release GroupImmediate Release GroupPlacebo Group
NauseaGastrointestinal disorders1/1202/1206/39
VomitingGastrointestinal disorders0/1202/1203/39
RashSkin and subcutaneous tissue disorders0/1200/1202/39
ChillsGeneral disorders0/1200/1201/39
Swelling faceGeneral disorders0/1201/1201/39
Alveolar osteitisInfections and infestations1/1201/1201/39
Tooth infectionInfections and infestations0/1200/1201/39
Product administration errorInjury, poisoning and procedural complications0/1200/1201/39
DizzinessNervous system disorders0/1200/1201/39
HeadacheNervous system disorders0/1202/1201/39

Baseline characteristics

One subject in the placebo group withdrew from the study before receiving the allocation intervention.

Age, Continuous
Age, Continuous(years)Prolonged Release GroupImmediate Release GroupPlacebo GroupTotal
Mean19.6 ± 2.0219.8 ± 2.4720.7 ± 3.1319.8 ± 2.42
Sex: Female, Male
Sex: Female, Male(Participants)Prolonged Release GroupImmediate Release GroupPlacebo GroupTotal
Female725324149
Male486715130
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Prolonged Release GroupImmediate Release GroupPlacebo GroupTotal
Hispanic or Latino1712837
Not Hispanic or Latino10110530236
Unknown or Not Reported2316
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Prolonged Release GroupImmediate Release GroupPlacebo GroupTotal
American Indian or Alaska Native1102
Asian3216
Native Hawaiian or Other Pacific Islander5229
Black or African American2103
White10710836251
More than one race1203
Unknown or Not Reported1405
Baseline Pain
Baseline Pain(units on a scale)Prolonged Release GroupImmediate Release GroupPlacebo GroupTotal
Mean7.5 ± 1.237.6 ± 1.177.8 ± 1.127.6 ± 1.19
Baseline Pain Category
Baseline Pain Category(Participants)Prolonged Release GroupImmediate Release GroupPlacebo GroupTotal
Moderate635715135
Severe576324144
Height
Height(cm)Prolonged Release GroupImmediate Release GroupPlacebo GroupTotal
Mean168.72 ± 9.753171.61 ± 8.517167.85 ± 6.223169.84 ± 8.917
Weight
Weight(kg)Prolonged Release GroupImmediate Release GroupPlacebo GroupTotal
Mean67.99 ± 13.93173.17 ± 13.92169.69 ± 12.04170.46 ± 13.847

2 further baseline measures are reported on the registry.

08

Study locations

1 site
  • JBR Clinical Research
    Salt Lake City, Utah 84107, United States
09

References and documents

Publications

  • Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole MR. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001 Nov;94(2):149-158. doi: 10.1016/S0304-3959(01)00349-9. PubMed 11690728 ↗
  • Davies NM. Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin Pharmacokinet. 1998 Feb;34(2):101-54. doi: 10.2165/00003088-199834020-00002. PubMed 9515184 ↗
  • Miles L, Hall J, Jenner B, Addis R, Hutchings S. Predicting rapid analgesic onset of ibuprofen salts compared with ibuprofen acid: Tlag, Tlow, Tmed, and a novel parameter, TCmaxRef. Curr Med Res Opin. 2018 Aug;34(8):1483-1490. doi: 10.1080/03007995.2018.1466697. Epub 2018 Apr 27. PubMed 29667449 ↗
  • Cooper SA, Desjardins PJ, Turk DC, Dworkin RH, Katz NP, Kehlet H, Ballantyne JC, Burke LB, Carragee E, Cowan P, Croll S, Dionne RA, Farrar JT, Gilron I, Gordon DB, Iyengar S, Jay GW, Kalso EA, Kerns RD, McDermott MP, Raja SN, Rappaport BA, Rauschkolb C, Royal MA, Segerdahl M, Stauffer JW, Todd KH, Vanhove GF, Wallace MS, West C, White RE, Wu C. Research design considerations for single-dose analgesic clinical trials in acute pain: IMMPACT recommendations. Pain. 2016 Feb;157(2):288-301. doi: 10.1097/j.pain.0000000000000375. PubMed 26683233 ↗
  • Singla NK, Desjardins PJ, Chang PD. A comparison of the clinical and experimental characteristics of four acute surgical pain models: dental extraction, bunionectomy, joint replacement, and soft tissue surgery. Pain. 2014 Mar;155(3):441-456. doi: 10.1016/j.pain.2013.09.002. Epub 2013 Sep 6. PubMed 24012952 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Feb 2020, 9 months.

Results were first posted in Jun 2024, 4 years 3 months after primary completion.

Of 105 industry-sponsored phase 3 interventional studies under Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 23. This study's 9 months is below that.

Counting every sponsor, half of 216 studies reached it within 18 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2018
First posted
Dec 24, 2018
StartActual
Apr 29, 2019
Primary completionActual
Feb 20, 2020
CompletionActual
Feb 28, 2020
Results first posted
Jun 3, 2024
Last update
Jun 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03785756
Collaborators
Premier Research Group plc
Responsible party
Sponsor
First posted
Dec 24, 2018
Start date
Apr 29, 2019
Primary completion
Feb 20, 2020
Completion
Feb 28, 2020
Results posted
Jun 3, 2024
Last update
Jun 3, 2024

Study contacts

Todd Bertoch, MD
principal investigator · JBR Clinical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion